Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07239323 | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | PHASE1 | RECRUITING | 24 | — | — | Jul 1, 2025 | Dec 31, 2028 | Nov 20, 2025 | 1 | China |
MTD will be determined based on Dose-Limiting Toxicity(DLTs) observed during the first 28 days of study treatment.
The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included.
| Arm | Type | Description |
|---|---|---|
| Invivo CAR-T | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Invivo CAR-T | BIOLOGICAL | Patients were enrolled and given a single dose of CAR-T injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 2 years. |
Inclusion Criteria: 1. Age ≥ 18 years old, gender unrestricted; 2. Confirmed diagnosis of relapsed/refractory malignant hematological tumors, including B-ALL, B-cell lymphoma and multiple myeloma; 3. ECOG performance status score 0-2, with an expected survival period of ≥ 3 months; 4. Blood routine...